Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market, Global Outlook and Forecast 2023-2029

Exocrine pancreatic insufficiency (EPI) refers to the condition wherein the body is unable to produce sufficient amounts of exocrine pancreatic enzymes, thus leading to difficulties in digesting food properly. The condition occurs due to the lack of sufficient enzymes necessary for fat digestion, amylases for starch digestion, and proteases for protein digestion.
This report aims to provide a comprehensive presentation of the global market for Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics. This report contains market size and forecasts of Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics in global, including the following market information:
Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics market was valued at US$ 3606.5 million in 2022 and is projected to reach US$ 4721.5 million by 2029, at a CAGR of 3.9% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Therapeutics Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics include AbbVie, Allergan, Nordmark Arzneimittel, Digestive Care, Janssen Pharmaceuticals, Cilian, Anthera Pharmaceuticals and AzurRx Biopharma, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Segment Percentages, by Type, 2022 (%)
    Therapeutics
    Diagnostics (Blood Tests, Endoscopic Ultra-sonography, Magnetic Resonance Imaging (MRI), and CT Scanning)
Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Segment Percentages, by Application, 2022 (%)
    Hospitals
    Ambulatory Surgical Centers
    Specialty Clinics
Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Segment Percentages, By Region and Country, 2022 (%)
    North America
        US
        Canada
        Mexico
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
        Nordic Countries
        Benelux
        Rest of Europe
    Asia
        China
        Japan
        South Korea
        Southeast Asia
        India
        Rest of Asia
    South America
        Brazil
        Argentina
        Rest of South America
    Middle East & Africa
        Turkey
        Israel
        Saudi Arabia
        UAE
        Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
    AbbVie
    Allergan
    Nordmark Arzneimittel
    Digestive Care
    Janssen Pharmaceuticals
    Cilian
    Anthera Pharmaceuticals
    AzurRx Biopharma
Outline of Major Chapters:
Chapter 1: Introduces the definition of Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics, market overview.
Chapter 2: Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics market size in revenue.
Chapter 3: Detailed analysis of Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.